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First, biotechnology, like any other rapidly developing techni-
cal area, requires a strong academic base for both training and 
research purposes. The current system of funding by NIH and 
NSF based on peer review of research proposals, has worked 
well at the national level in research universities and should 
be continued. However, problems remain in areas such as the 
academic preparation of high school students in basic disci-
plines such as math, science, reading and communications 
skills, problems which are the province of state and local 
administration. 
Second, it must be recognized that while the United States • 
leads in many areas of high technology, including the princi-
pal components of biotechnology, our ability to successfully 
commercialize that technology is under tremendous competi-
tive pressure from Europe and japan. Much has recently been 
written about the death of the competitive spirit in America. 
This debate misses the point. Whatever the state of the Ameri-
can competitive spitit, that spirit is very much alive and well in 
the rest of the world. This is particularly true in biotechnology, 
a technology that easily crosses borders in the form of scien-
tific publications and international technical meetings. Stu-
dents from other countries, trained in U.S. research institu-
tions, return home to work in industrial and academic 
facilities with colleagues that equal , in most respects, those in 
the United States. A sense of complacency in matters relating 
to biotechnology would certainly have the same predictable 
result for the United States economy that is currently being 
seen in the automotive and electronics industries. 
Third, we need a better informed public. In many areas of 
high technology, the United States is becoming a two-tiered 
society: the minority who know about and understand the 
technology and its implications and the rest, who don't. This 
has several undesirable consequences including the abdica-
tion of decisionmaking power to the knowledgeable minority 
leading inevitably to mistrust, overregulation, and lost oppor-
tunities. It also diminishes the attractiveness of a technical 
career, reducing the number of U.S. students pursuing 
advanced technical education, and forcing U.S. academic insti-
tutions to go abroad in search of adequately prepared stu-
dents .< Obviously, this accelerates the development of strong 
foreign competition in high-technology fields, including 
biotechnology. 
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I would like to present my views on the promise and 
potential of biotechnology as it relates to the animal health-
care industry. Using various examples, some of which are 
based on experiences at Molecular Genetics, I will attempt to 
discuss current and future barriers to commercializing bio-
technology in this area, review what progress has been made 
to date in the animal healthcare field, and briefly touch on 
some policy issues relating to the above. 
Recombinant DNA-derived bovine somatotropin (rDNA-
bGH) or growth hormone is clearly one of the most visible 
animal healthcare products to undergo commercialization. 
The promise of biotechnology for this hormone is the poten-
tial to produce huge quantities of this protein at a very eco-
nomical cost. Current estimates claim that rDNA-bGH will cost 
about five cents a dose, and that thousands of kilograms will 
be produced annually for the dairy and beef cattle markets. 
Treatment of cattle with this synthetic form of a naturally 
occurring hormone may result in a 15% increase in milk 
production and a 10 to 15% increase in feed conversion 
efficiency. These figures mean that farmers will be able to 
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produce significantly more milk and meat per animal while 
using the same, or perhaps, less feed costs resulting in 
cheaper costs of production. 
Unlike many other extravagant promises you hear from 
biotechnology advocates, the benefits of rDNA-bGH are real 
and attainable in the near term. Only a few technical barriers 
prevent rDNA-bGH from reaching the marketplace; few other 
rDNA-derived proteins or substances can make that claim. 
With rDNA-bGH, the barriers to commercialization are either 
in marketing or regulatory approval. The market issues con-
cern the impact increased milk production will have on the 
price support structure within the dairy industry. There is a 
very real danger in producing 15% more milk per year without 
reducing the number of producing animals. With introduction 
of rDNA-bGH, dairy farmers will have to consider reducing the 
size of their herds so that the real benefit from using this 
hormone can be realized (i.e., reduced labor and feed costs). 
The public should not fear rDNA-bGH because of the science 
or technology involved or because milk may contain the 
hormone (native bGH has probably been in the milk you have 
Journal of the Minnesota Academy of Science 
been drinking since birth). What the public ought to be 
concerned with is the economic impact this hormone will 
have on the food industty in this country. 
The animal vaccine industry is my second example of the 
promise and pitfalls of biotechnology. Molecular Genetics 
was founded on the premise that biotechnology, more specif-
ically recombinant DNA technology, could make safer, more 
efficacious viral and bacterial vaccines. We believed that all 
that was necessary was to clone and express the viral genes 
coding for those viral coat proteins known to induce immun-
ity in bacteria. The promise of the technology was the availa-
bility of cheap, efficacious, and safe vaccines. Unfortunately, 
biotechnology has not borne the bountiful "fruit" everyone 
had expected. In human medicine, there have been some 
stunning successes. Chiron Corp., in conjunction with Merck, 
Sharpe, and Dohme, has produced an effective hepatitis B 
vaccine manufactured in yeast. The virtues of an rDNA-derived 
hepatitis B vaccine are many, the principal of which is that it is 
free of any contaminating infectious agents. In animal health-
care, however, there are no equivalent success stories. 
Although a few rDNA-derived vaccines have been developed 
for certain animal pathogens, similar vaccines for viral and 
bacterial diseases of economic importance in livestock have 
not been introduced. Many biotechnology companies, includ-
ing Molecular Genetics, spent considerable time and money 
in developing rDNA-derived vaccines for a $100 to 110 million 
annual market (U.S.) , and have very little to show for their 
efforts. 
However, some technology that evolved out of ill-fated 
rDNA vaccine projects has given companies like Molecular 
Genetics a second opportunity to develop relatively inexpen-
sive, effective vaccines. I like to call this technology "middle-
tech" versus the "high tech" of rDNA technology. I believe that 
middle-tech holds as much promise as rDNA technology for 
revolutionizing vaccine development in both humans and 
animals for several reasons. Middle-tech represents a conglo-
meration of techniques embodied under the term biotech-
nology, none of which are associated with recombinant DNA 
technology per se. Middle-tech encompasses such methods as 
liquid chromatography, hybridoma/ monoclonal antibody 
technology, analytical and preparative electrophoresis, and 
other techniques. These techniques can be used in various 
combinations to isolate and purify components of viruses and 
bacteria, which can then be used to prepare vaccines. 
The advantages of middle-tech are many. First, the afore-
mentioned techniques can be used with naturally occurring 
viruses and bacteria. Native proteins of most pathogens are 
generally antigenic and can adequately stimulate a protective 
response from an animal's immune system, which has not 
always been the case with rDNA-derived proteins. Second, the 
regulatory issues surrounding middle-tech do not appear to 
be as formidable as those associated with rDNA technology. 
Third, less sophisticated labor is involved in manufacture and 
quality control, which can reduce the costs of production. 
There are already some examples of successful products 
jeveloped through middle-tech . Molecular Genetic's 
::;enecol (R) 99 monoclonal antibody against coliform scours 
Volume 53, Number 1, 1987/ 88 
or diarrhea in calves has proven to be very successful in the 
market. I believe it remains the only proven monoclonal 
therapeutic product on the market. 
Another Molecular Genetics product that has entered regu-
latory testing is a therapeutic monoclonal antibody against a 
swine herpes virus called pseudorabies virus (PRY). PRY is an 
economically devastating disease of swine. It is a regulated 
disease, meaning that infected animals are quarantined and 
severe restrictions are imposed on movement of the animals. 
Accurate diagnosis of the disease is complicated because a 
reliable diagnostic is not available to differentiate vaccinated 
animals from naturally infected ones. Moreover, conventional 
PRY vaccines have been relatively ineffective in preventing 
this disease. However, animals receiving a subunit vaccine 
that contained one or two principal antigens (viral coat pro-
teins) could be differentiated from naturally infected ones 
using a compatible diagnostic. Molecular Genetics has used 
middle-tech to develop a commercially acceptable vaccine 
and compatible diagnostic for PRY. In this case, a monoclonal 
antibody to certain PRY coat proteins is used to isolate and 
purify these subunit proteins for formulation into a vaccine. 
The protein(s) that remain(s) are subsequently used in the 
diagnostic test. This vaccine/ diagnostic combination product 
means that the swine producer can protect the pigs while 
preventing them from being quarantined. 
As my examples have shown, the technology exists today to 
produce a new generation of vaccines and therapeutics that 
do not necessarily rely on recombinant DNA technology. I am 
somewhat disappointed that more progress has not been 
made in recent years. Perhaps progress has been hindered 
because of the biotechnology industry's insistence on viewing 
projects and, to a lesser degree, company missions as 
dependent on singular, high visibility techniques such as 
recombinant DNA Millions of dollars have been spent by the 
U.S. government, the biotechnology and pharmaceutical 
industries, and academia attempting to develop better subunit 
vaccines, via recombinant DNA technology, for foot and 
mouth disease, a major viral disease of cattle outside the 
continental United States. To date, none of these efforts has 
proven successful in. producing a safer, more efficacious vac-
cine than that currently available on the market. Perhaps if 
those same monies had been used to develop middle-tech 
approaches, a new generation foot and mouth disease vaccine 
would be undergoing regulatory testing at this time. 
In essence, I am here today to argue that you carefully study 
the latest technology that is being espoused as the next great 
leap forward . A company that is based on a single technical 
approach is risking failure because it lacks the alternative 
resource or resources to ensure success. A successful 
approach to a biological problem should encompass a 
number of backup techniques that will yield the process or 
product desired. Biotechnology, as a field, certainly provides a 
rich repertoire of techniques and the future looks very bright 
for the development of more powerful and sophisticated 
approaches. Commercial success in the biotechnology indus-
try will ultimately depend on careful selection of the right 
complement of technologies. 
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